

DAVID WEISMAN, M.D.

ADDRESS/PHONE NUMBERS

Abington Neurological Associates
dcweisman@gmail.com

1151 Old York Rd STE 200. Abington, PA 19001
203-444-2912

APPOINTMENTS

2008- Director and Founder of Abington Neurological Associates: Clinical Research Center
2006- Neurologist, Abington Neurological Associates
2009-18 Clinical Assistant Professor, Temple University School of Medicine
2013-14 Director, Dementia Society of America, Inc.
2004-2006 Staff Physician, UCSD Neurology Department
2002-2004 Consultative examiner, State of Connecticut, Department of Public Health
2003-2004 Courtesy Staff, Branford Hospice, Branford, CT

TRAINING

2004-2006 University California San Diego, San Diego, CA.
 Dementia/Behavioral Neurology Fellow
2003-2004 Yale New Haven Hospital, New Haven, CT
 Chief Resident Neurology
2001-2004 Yale New Haven Hospital, New Haven, CT
 Neurology Resident
2000-2001 St. Mary's Hospital, San Francisco, CA
 Internal Medicine Internship

EDUCATION

1996-2000 Pennsylvania State University College of Medicine, Hershey, PA
 M.D. May, 2000
1992-1996 Franklin and Marshall College, Lancaster, PA
 BA. Philosophy, Cum Laude, May, 1996
1988-1992 Bethlehem Catholic HS, Bethlehem, PA

CERTIFICATION

Pennsylvania State License: 2006 – ongoing
National Board of Physicians and Surgeons (NBPAS): 2015-ongoing
Neurology boards. 2006
Neurology vascular boards. 2008
Connecticut State License: 2002 – 2004
California State License: 2004 – 2006
United States Medical Licensing Examination. Step 1: June, 1998; Step 2: April, 1999; Step 3: July, 2001

CLINICAL RESEARCH

2024 Site Principal Investigator (PI), START trial, CT1812 in AD (Cognition, NIA, ATRI) NCT05531656
2024 Site PI, Altitude-AD, phase 2, antibody against amyloid oligomers in AD (Acumen)
2024 Site PI, Radiant ACP-204 in AD psychosis (Acadia) NCT06159673
2024 Site PI, Frexalimab (SAR441344) Relapsing Multiple Sclerosis (Sanofi) NCT06141473
2023 Site PI, SAGE-718 in with Alzheimer's Disease. (Sage) NCT05619692
2022- Site PI, Viva-Mind, prevent pyroglutamate amyloid. (Vivoryon) NCT03919162
2022- Site PI, Envision, aducanumab in early Alzheimer's disease, phase IIIb (AD (Biogen) NCT05310071
2022-24 Site PI, buntanetap in Parkinson's disease, phase III (Annovis) NCT05357989
2022- Site PI, MTAE. Anti-tau oligomers prevent NAC on tau. (Lilly) NCT05063539
2022-23 Site PI, Padova, antibody against a-synuclein in Parkinson's disease BN42358 (Roche) NCT04777331

2022-23 Site PI, LID in Parkinson's, AX48621 (Addex) NCT04928287
2022-23 Site PI, Intercept, phase 1 antibody against amyloid oligomers (Acumen) NCT04931459
2022-22 Site PI, ICare, aducanumab observational (Biogen) NCT05097131
2022-23 Sub-investigator, GWSP18023. MS spasticity with Nabiximol (GW Pharma) NCT04203498
2022- Sub-investigator, Pitolisant. Idiopathic Hypersomnia phase III. (Harmony) NCT05156047
2022- Sub-investigator, M21-307 Preclude study Migraine (AbbVie) NCT05028569
2022- Sub-investigator, M23-072 Ubrogepant in Subjects Taking Atogepant (AbbVie) NCT05264129
2021-23 Site PI, anti-oligomer for early APOE44 homozygous in AD, phase III (Alzheon) NCT03634007
2021- Site PI, Apathy in AD (Cerevel) NCT04958031
2021-23 Site PI, donanemab vs. aducanumab in early AD, AACN (Lilly) NCT05108922
2021-23 Site PI, Brain shuttle, phase 1b in mild-mod AD (Roche) NCT03522129
2020- Site PI, Ahead trial, BAN2401 in Alzheimer's disease prevention (Eisai) NCT04468659
2020-22 Site PI, GV-971 in mild to mod Alzheimer's disease, phase III (Green Valley) NCT04520412
2020-24 Site PI, Evobrutinib: BTK inhibition in multiple sclerosis, phase III (Sero) NCT04411641
2020-23 Site PI, Weekly gantenerumab in AD, phase III (Roche) NCT03443973
2020-23 Site PI, AACI Donanemab in Alzheimer's, phase III (Lilly) NCT04437511
2020-22 Site PI, AL002, mab against TREM2, phase II (Alector) NCT04592874
2020- Site PI, High dose of ocrelizumab in relapsing and primary progressive MS (Roche) NCT05285891
2019-20 Site PI, Etheral, Epigenetic THERapy in Alzheimer's Disease (Oryzon)
2019-22 Site PI, Sub-cutaneous L-dopa and C-dopa in PD. ND0612 (Neuroderm) NCT04006210
2019-20 Site PI, Pridopidine vs. Placebo in Levodopa-Induced Dyskinesia (Prilenia) NCT03922711
2019-20 Site PI, Presence, dopamine receptor modulator in PD and DLB (Lilly) NCT02225106
2019-21 Sub-investigator, atogepant in prevention of migraine (Allergan) NCT04437433
2018-23 Site PI, Graduate: gantenerumab in AD (Roche) NCT03444870
2018-20 Site PI, Intravenous Neridronic Acid in CRPS within two years. (Grünenthal) NCT03530345
2018-20 Site PI, Tri-protect, BHV-4157 in AD (BioHaven) NCT03605667
2017-20 Site PI, Trailblazer, AACG: donanemab Alzheimer's, phase II (Lilly) NCT03367403
2017-20 Site PI, Anti-Lingo for remyelination in MS, phase II (Biogen) NCT03222973
2017-23 Site PI, S-CitAD, agitation in Alzheimer's, Phase IV (John Hopkins) NCT00898807
2017-18 Site PI, LLCF: BACEI in Alzheimer's to prevent Tau spread, phase II (Lilly) NCT02791191
2017-18 Site PI, Pimvanserin in Psychosis and Dementia, phase III (Acadia) NCT02970292
2018-18 Site PI, NPT189 in Alzheimer's disease, phase Ib (Proclara) NCT03610035
2016-20 Site PI, CAD106, CNP520 in Alzheimer's Disease prevention (Banner, Novartis) NCT02565511
2016-17 Site PI, Intepirdine for DLB, Intepirdine for AD (Axovant) NCT02910102
2016-19 Site PI, Crenezumab in Alzheimer's Disease trial. Phase III (Roche) NCT02670083
2016-17 Site PI, PF-06649751 in motor fluctuations due to Parkinson's disease (Pfizer) NCT02687542
2016-17 Site PI, Tozadenant in Levodopa-Treated Patients With Parkinson's Disease (Biotie) NCT03051607
2016-17 Site PI, pimavanserin in agitation in AD. (Acadia) NCT02035553
2016-17 Site PI, CVT-301 in Parkinson's disease, phase III (Acorda Therapeutics) NCT02240030
2015-17 Site Sub-I, LY2951742 in chronic migraine, phase III (Lilly) NCT04616326
2015-18 Site PI, AVP-786 for Agitation in Patients with Alzheimer's Disease. (Avanir) NCT04408755
2014-17 Site PI, gantenerumab in Mild Alzheimer's Disease, Phase III. (Roche/Genentech) NCT02051608
2015-17 Site PI, IV Neridronic Acid in CRPS-I, Phase II-III. (Grünenthal) NCT02972359
2014-17 Site PI, Baclofen ER Capsules in MS Spasticity, phase III (Sun Pharma) NCT01743651
2014-20 Sub-investigator, Fingolimod in MS, Observational study. Phase IV (Novartis) NCT03623243
2014-17 Sub-investigator, ALD403 in Chronic Migraine, Phase II study. (Alder) NCT02974153
2014-16 Site PI, T-817MA in Alzheimer's Disease, Phase II study. (Toyama) NCT02079909
2014-17 Site PI, MK – 8931 in Prodromal AD, Phase III study. (Merck) NCT01953601
2013-16 Site PI, MK – 8931 in Alzheimer's disease, Phase II/III study (Merck) NCT01496170
2013-15 Site PI, Tecfidera in MS, Observational Study. (ESTEEM) (Biogen) NCT02047097
2015-16 Site PI, INSPIRE, Tecfidera in secondary progressive MS. (Biogen) NCT02430532
2014-15 Site PI, Plovamer Acetate compared to Copaxone in MS, Phase II. (Merck-Serono) NCT01963611
2014-15 Site PI, EVP – 6124 in Alzheimer's disease, Phase III. (Envivo) NCT01969136
2013-15 Site PI, AC – 1204 in Alzheimer's disease, Phase III. (Accera) NCT01741194
2013-15 Site PI, Oral ELND005 in AD Agitation, Phase II/III. (Transition) NCT01735630
2013-18 Site PI, BAN2401 in Alzheimer's Disease, Phase IIb study. (Eisai) NCT01767311
2011-12 Site PI, Predalant in Parkinson's disease, Phase III study. (Merck) NCT01155466

- 2011-16 Site PI, ocrelizumab in MS, phase III study. (Roche) NCT01412333
 2014-15 Site co-PI, ESCAPE trial in acute stroke. NCT01778335
 2014-17 Sub-investigator, Dabigatran Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (Boehringer Ingelheim) NCT02239120
 2013-18 Site PI, Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial (NIH, UVA) NCT01369069
 2011-12 Sub-investigator, IMS-III, endovascular intervention in stroke. (NIH) NCT00359424
 2010-17 Sub-investigator, POINT trial in TIA and mild stroke. (NIH) NCT00991029
 2008-12 Site PI, Bapineuzumab: all phase III and IV studies. (Elan, Wyeth, Pfizer)
 2008-10 Site PI, Oral ELND005 in Alzheimer's disease. Phase II study. (Elan) NCT00568776
 2006, 09 Site PI, Albumin in Ischemic Stroke Study, ALIAS (NIH). NCT00235495
 2004-06 Site PI, UCSD. Alzheimer's Disease Cooperative Study, Anti-oxidant 1b trial. NCT00117403
 2005 Sub-I, UCSD: ADCS, Bapineuzumab. Phase II study. (Elan) NCT00112073
 2004-05 Sub-I, UCSD: Prospective Huntington At Risk Observational Study (PHAROS). NCT00052143
 2005 Sub-I, UCSD: Phenylbutyrate in subjects with Huntington's disease. Phase II study. NCT00212316

FOOD AND DRUG ADMINISTRATION

- 2023 Peripheral and Central Nervous System Drugs Advisory Committee, Temporary Voting Member.

PUBLICATIONS, ESSAYS, POSTERS, AND ABSTRACTS

- 2023 Sagar R, Zivko C, Xydia A, Weisman DC, Lyketsos CG, Mahairaki V. Generation and Characterization of a Human-Derived and Induced Pluripotent Stem Cell (iPSC) Line from an Alzheimer's Disease Patient with Neuropsychiatric Symptoms. *Biomedicines*. 2023; 11(12):3313.
 2023 Newby D, Orgeta V, Marshall CR, Lourida I, Albertyn CP, Tamurin S, Raymont V, Veldsman M, Koychev I, Llewellyn DJ, Ranson JM et al.. "Artificial Intelligence for Dementia Prevention." *Alzheimer's & Dementia*. 2023.
 2022 Daly T, Weisman D. "Questionnaire-based Computer Assisted Diagnosis (Q-CADx) is useful for identifying Alzheimer's Disease" CTAD poster.
 2020 Anderson D, Nathan D, Cassar E, Warraich R, Weisman D. "The Methodology and Probability of Recruitment and Enrollment Into Phase II and III Alzheimer's Disease and Mild Cognitive Impairment Clinical Research Trials" CTAD abstract and presentation
 2017 Weisman D, Liu E. ARIA-H follow up at 7.5 years. Do microhemes beget microhemes? AAIC poster.
 2016 Arch A, Weisman D, Coca S, Nystrom K, Wira C, Schindler J. Missed Ischemic Stroke Diagnosis in the Emergency Department by Emergency Medicine and Neurology Services. *Stroke* 2016;47:668-673
 2015 Weisman D, Khoury J, Kulandaivel K, Amberker D, Sleiman P. Validation of the Philadelphia Cognitive Exam (P-Cog): A Rapid, Tablet-Computer Based Dementia Screening Test. AAIC poster.
 2015 Hill MD, Martin RH, Palesch YY, Moy CS, Tamariz D, Ryckborst KJ, Jones EB, Weisman D, Pettigrew C, Ginsberg MD. Albumin administration in acute ischemic stroke: Safety analysis of the ALIAS Part 2 Multicenter Trial. *PLoS One*
 2015 Chapter 4. Dissolution into Death: They Mind's last Symptoms Indicate Annihilation in *The Myth of an Afterlife: The Case against Life after Death*. Rowman & Littlefield.
 2007 Weisman D, Yaari R, Hansen L, Thal L. Density of the Brain, Decline of the Mind: An Atypical Case of Fahr Disease. *Arch Neurol*. 2007;64(5):756-757
 2007 Weisman D, McKeith I. Dementia with Lewy bodies. *Semin Neurol*. 2007 Feb;27(1):42-7.
 2007 Weisman D, Cho M, Taylor C, Adame A, Thal LJ, Hansen LA. In dementia with Lewy bodies, Braak stage determines phenotype, not Lewy body distribution. *Neurology*. 2007 Jul 24;69(4):356-9.
 2007 Weisman D, Hakimian E, Ho GJ. Interleukins, inflammation, and mechanisms of Alzheimer's disease. *Vitam Horm*. 2006;74:505-30.
 2006 Rasmusson A, Pinna G, Paliwal P, Weisman D, Gottschalk C, Krystal J, Guidotti a. Decreased CSF Allopregnanolone in Women with PTSD, *Arch Gen Psych*. 2006 Oct 1;60(7):704-13
 2006 Corey-Bloom J, Yaari R, Weisman D. Managing patients with Alzheimer's disease. *Practical Neurology*. 6: 78-89.
 2005 Weisman D, Adame A, Taylor C, Thal L, Hansen L. Braak Stage Trumps Lewy Body Distribution. Abstract, plenary session at AAN national meeting.
 2003 Weisman D, Hisama F, Waxman SG, and Blumenfeld H. Going deep to cut the link: Cortical disconnection syndrome caused by a thalamic lesion. *Neurology* 2003;60: 1865-1866.

COLLABORATING AUTHORSHIPS

- 2022 Teng E, Manser PT, Pickthorn K, Brunstein F, Blendstrup M, Sanabria Bohorquez S, Wildsmith KR, Toth B, Dolton M, Ramakrishnan V, Bobbala A, Sikkes SAM, Ward M, Fuji RN, Kerchner GA; Tauriel Investigators. Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease: A Randomized Clinical Trial. *JAMA Neurol.* 2022 Aug 1;79(8):758-767. doi: 10.1001/jamaneurol.2022.1375.
- 2022 McDonough RV, Ospel JM, Majoie CBLM, Saver JL, White P, Dippel DWJ, Brown SB, Demchuk AM, Jovin TG, Mitchell PJ, Bracard S, Campbell BCV, Muir KW, Hill MD, Guillemin F, Goyal M; HERMES collaborators. Clinical outcome of patients with mild pre-stroke morbidity following endovascular treatment: a HERMES substudy. *J Neurointerv Surg.* 2022 Feb 24.
- 2021 Ganesh A, Ospel JM, Menon BK, Demchuk AM, McTaggart RA, Nogueira RG, Poppe AY, Almekhlafi MA, Hanel RA, Thomalla G, Holmin S, Puetz V, van Adel BA, Tarpley JW, Tymianski M, Hill MD, Goyal M; ESCAPE-NA1 Trial Investigators. Assessment of Discrepancies Between Follow-up Infarct Volume and 90-Day Outcomes Among Patients With Ischemic Stroke Who Received Endovascular Therapy. *JAMA Netw Open.* 2021 Nov 1;4(11):e2132376.
- 2020 Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, Cross AH, de Seze J, Leppert D, Montalban X, Selmaj K, Wiendl H, Kerloeguen C, Willi R, Li B, Kakarieka A, Tomic D, Goodyear A, Pingili R, Häring DA, Ramanathan K, Merschhemke M, Kappos L; ASCLEPIOS I and ASCLEPIOS II Trial Groups. Ofatumumab versus Teriflunomide in Multiple Sclerosis. *N Engl J Med.* 2020 Aug 6;383(6):546-557.
- 2020 Hill MD, Goyal M, Menon BK, Choe H, Tymianski M et al; ESCAPE-NA1 Investigators. Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial. *Lancet.* 2020 Feb 20. pii: S0140-6736(20)30258-0.
- 2019 Schneider LS, Thomas RG, Hendrix S, Rissman RA, Brewer JB, Salmon DP, Oltersdorf T, Okuda T, Feldman HH, Safety and Efficacy of Edonerpic Maleate for Patients With Mild to Moderate Alzheimer Disease. *JAMA Neurol.* July 8, 2019.
- 2019 Johnston KC, Bruno A, Pauls Q, et al; Neurological Emergencies Treatment Trials Network and the SHINE Trial Investigators. Intensive vs Standard Treatment of Hyperglycemia and Functional Outcome in Patients With Acute Ischemic Stroke: The SHINE Randomized Clinical Trial. *JAMA.* 2019 Jul 23;322(4):326-335.
- 2018 Liu E, Wang D, Sperling R, Salloway S, Fox NC, Blennow K, Scheltens P, Schmidt ME, Streffer J, Novak G, Einstein S, Booth K, Ketter N, Brashear HR; ELN115727-301/302 Investigator Group. Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab. *Neurology.* 2018 Mar 6;90(10):e877-e886.
- 2018 Johnston SC, Easton JD, Farrant M, et al. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA. *N Engl J Med.* 2018. May; DOI: 10.1056/NEJMoa1800410
- 2017 Campbell BCV, van Zwam WH, Goyal M, Hill MD, Mitchell PJ et al. Effect of general anaesthesia on functional outcome in patients with anterior circulation ischaemic stroke having endovascular thrombectomy versus standard care: a meta-analysis of individual patient data. *Lancet Neurol.* 2018 Jan;17(1):47-53.
- 2017 Hauser SL1, Bar-Or A1, Comi G1, Giovannoni G1, Hartung HP1, Hemmer B1, Lublin F1, Montalban X1, Rammohan KW1, Selmaj K1, Traboulsee A1, Wolinsky JS1, Arnold DL1, Klingelschmitt G1, Masterman D1, Fontoura P1, Belachew S1, Chin P1, Mairon N1, Garren H1, Kappos L1; OPERA I and OPERA II Clinical Investigators. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. *N Engl J Med.* 2017 Jan 19;376(3):221-234.
- 2015 Liu E, Schmidt ME, Margolin R, Sperling R, Koeppe R, Mason NS, Klunk WE, Mathis CA, Salloway S, Fox NC, Hill DL, Les AS, Collins P, Gregg KM, Di J, Lu Y, Tudor IC, Wyman BT, Booth K, Broome S, Yuen E, Grundman M, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators. Amyloid- β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials. *Neurology.* 2015 Aug 25;85(8):692-700..
- 2015 Goyal M1, Demchuk AM, Menon BK, Eesa M, Rempel JL, Thornton J, Roy D, Jovin TG, Willinsky RA, Sapkota BL, Dowlathshahi D, Frei DF, Kamal NR, Montanera WJ, Poppe AY, Ryckborst KJ, Silver FL, Shuaib A, Tampieri D, Williams D, Bang OY, Baxter BW, Burns PA, Choe H, Heo JH, Holmstedt CA, Jankowitz B, Kelly M, Linares G, Mandzia JL, Shankar J, Sohn SI, Swartz RH, Barber PA, Coutts SB, Smith EE, Morrish WF, Weill A, Subramaniam S, Mitha AP, Wong JH, Lowerison MW, Sajobi TT, Hill MD; ESCAPE Trial Investigators. Randomized assessment of rapid

- endovascular treatment of ischemic stroke. *N Engl J Med.* 2015 Mar 12;372(11):1019-30. doi: 10.1056/NEJMoa1414905. Epub 2015 Feb 11.
- 2014 Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. *N Engl J Med.* 2014 Jan 23;370(4):322-33.
- 2012 Galasko DR1, Peskind E, Clark CM, Quinn JF, Ringman JM, Jicha GA, Cotman C, Cottrell B, Montine TJ, Thomas RG, Aisen P; Alzheimer's Disease Cooperative Study. Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures. *Arch Neurol.* 2012 Jul;69(7):836-41.
- 2003 Medical Reviewer. *Migraine.* Joan Raymond, Sterling Publishing Co. Oct 2002. 076073982X.

OTHER PRESS PUBLICATIONS

- 2011 Weisman D. Buddhism and the Brain. *Seed Magazine.* Opinion 2011; March. Translated and published as 'Lost Consciousness' in *Esquire Russia.* 2011. July-Aug
- 2011 Weisman D. Disposable Heroes. *Seed Magazine.* Opinion 2011; Jan 11. Reprinted in *The St. Martin's Guide to Writing 10/e.* 2013 | ISBN-10: 1457654385. Bedford/Saint Martin's
- 2010 Weisman D. Divided Minds, Specious Souls. *Seed Magazine.* Opinion 2010; Sep 21.
- 2009 Weisman D. Questioning IA approach. *Clinical Neurology News.* July 2009 Vol. 5, Issue 6, 5.
- 2008 Weisman D, Cho M, Taylor C, Adame A, Thal LJ, Hansen LA. Comment. *Neurology.* 2008 May 27;70(22):2087-8

MANUSCRIPT AND PRESS REVIEWER

International Journal of Stroke
American Journal of Alzheimer's Disease & Other Dementias
Everyday Health Editorial

INVITED PRESENTATIONS

- 2023 Novel AD Drugs. Temple University. Grand Rounds.
- 2023 AAIC. Alz-Net Site Perspective.
- 2020 Amyloid, AD, trials. Abington Memorial Hospital. Neurovascular Conference.
- 2008 Alzheimer's disease. Abington Memorial Hospital Grand Rounds.
- 2005 Alzheimer's disease: a long way from August D. UCSD Department of Geriatric Psychiatry
- 2004 Shaken: Seizures for the Psychiatrist. Yale Department of Psychiatry, Neurology Series
- 2003 The Deprived Brain: Reorganization Following Deafferentation
Yale Department of Neurology, Grand Rounds
- 2002 Cortical Signs, Thalamic Lesions, Corticothalamic Relations
Yale Department of Neurology, Grand Rounds

TEACHING EXPERIENCE

- 2008-17 Teacher, Salus University PA program, neurology.
- 2012 Teacher, Arcadia University PA program, neurology.

HONORS & AWARDS & DISTINCTIONS

- 2022 Strava segment leaderboard 'SuperSecret-Down' 4th fastest.
- 2016 National Coordinator, Roche, CREAD (Crenezumab in Alzheimer's Disease) trial.
- 2014 Listed among Alzheimer's Disease Cooperative Study (ADCS) clinical sites
- 2014 Innovator Award, Abington Memorial Hospital, development of a computerized cognitive test.
- 2012 IMS-III: site winner for shortest door to intravascular stroke treatment.
- 2004 Annual Teaching Award, Department of Neurology, Yale
- 2004 American Academy of Neurology: Resident Scholarship to Annual Meeting
- 1996 Alpha Epsilon Delta: Medical Honor Society

PERSONAL

Mountain biking, running.

Created and developed iPad app: Philadelphia Cognitive Exam (P Cog). A computer based cognitive test and expert system to help diagnose and manage memory disorders.

Created and developed a digital tracking system: Medtraker.com. A web based tracking system for patients requiring administration of drugs with complex monitoring requirements.